{"title": "Dosis altas de multivitaminas en comparaci\u00f3n con un placebo para prevenir la recurrencia del c\u00e1ncer en pacientes con c\u00e1ncer de vejiga en estadio temprano", "author": null, "url": "https://ichgcp.net/es/clinical-trials-registry/NCT00003623", "hostname": "ichgcp.net", "description": "FUNDAMENTO: La terapia de quimioprevenci\u00f3n es el uso de ciertos medicamentos para tratar de prevenir el desarrollo o la recurrencia del c\u00e1ncer. El uso de multiv.... Registro de ensayos cl\u00ednicos. ICH GCP.", "sitename": "ichgcp.net", "date": "1999-11-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Dosis altas de multivitaminas en comparaci\u00f3n con un placebo para prevenir la recurrencia del c\u00e1ncer en pacientes con c\u00e1ncer de vejiga en estadio temprano\n[Alliance for Clinical Trials in Oncology](https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Alliance%20for%20Clinical%20Trials%20in%20Oncology)\nMegadosis de vitaminas como quimioprevenci\u00f3n del carcinoma de c\u00e9lulas de transici\u00f3n de la vejiga\nFUNDAMENTO: La terapia de quimioprevenci\u00f3n es el uso de ciertos medicamentos para tratar de prevenir el desarrollo o la recurrencia del c\u00e1ncer. El uso de multivitaminas en dosis altas puede ser una forma eficaz de prevenir la recurrencia del c\u00e1ncer de vejiga en etapa inicial. Todav\u00eda no se sabe si las dosis altas de vitaminas son m\u00e1s efectivas que ninguna otra terapia para disminuir el riesgo de c\u00e1ncer de vejiga en etapa temprana.\nPROP\u00d3SITO: Ensayo de fase III aleatorizado, doble ciego, para comparar la efectividad de las multivitaminas en dosis altas con un placebo para prevenir la recurrencia del c\u00e1ncer en pacientes con c\u00e1ncer de vejiga en estadio temprano.\nDescripci\u00f3n general del estudio\nEstado\nCondiciones\nIntervenci\u00f3n / Tratamiento\nDescripci\u00f3n detallada\nOBJETIVO: I. Determinar si las dosis altas de multivitaminas tienen una eficacia quimiopreventiva m\u00e1s all\u00e1 de la terapia est\u00e1ndar para reducir el riesgo de recurrencia en pacientes con carcinoma de c\u00e9lulas transicionales de vejiga en estadio 0 e I (Ta, T1 y Tis) resecado.\nESQUEMA: Este es un estudio aleatorizado, doble ciego. Los pacientes se aleatorizan para recibir multivitam\u00ednicos o placebo por v\u00eda oral una vez al d\u00eda durante 3 a\u00f1os. Los pacientes son seguidos cada 3 meses durante 2 a\u00f1os, luego cada 6 meses durante 1 a\u00f1o y luego anualmente a partir de entonces.\nTipo de estudio\nInscripci\u00f3n (Actual)\nFase\n- Fase 3\nContactos y Ubicaciones\nUbicaciones de estudio\n-\nCanad\u00e1\n-\nSaskatchewan\n-\nRegina, Saskatchewan, Canad\u00e1, S4T 7T1\n- Allan Blair Cancer Centre\n-\n-\n-\nEstados Unidos\n-\nArizona\n-\nScottsdale, Arizona, Estados Unidos, 85259-5404\n- CCOP - Scottsdale Oncology Program\n-\n-\nIllinois\n-\nUrbana, Illinois, Estados Unidos, 61801\n- CCOP - Carle Cancer Center\n-\n-\nIowa\n-\nCedar Rapids, Iowa, Estados Unidos, 52403-1206\n- CCOP - Cedar Rapids Oncology Project\n-\nDes Moines, Iowa, Estados Unidos, 50309-1016\n- CCOP - Iowa Oncology Research Association\n-\nSioux City, Iowa, Estados Unidos, 51101-1733\n- Siouxland Hematology-Oncology\n-\n-\nKansas\n-\nWichita, Kansas, Estados Unidos, 67214-3882\n- CCOP - Wichita\n-\n-\nMichigan\n-\nAnn Arbor, Michigan, Estados Unidos, 48106\n- CCOP - Ann Arbor Regional\n-\n-\nMinnesota\n-\nDuluth, Minnesota, Estados Unidos, 55805\n- CCOP - Duluth\n-\nRochester, Minnesota, Estados Unidos, 55905\n- Mayo Clinic Cancer Center\n-\nSaint Cloud, Minnesota, Estados Unidos, 56303\n- CentraCare Clinic\n-\n-\nNorth Dakota\n-\nBismarck, North Dakota, Estados Unidos, 58501\n- Medcenter One Health System\n-\nFargo, North Dakota, Estados Unidos, 58122\n- CCOP - Merit Care Hospital\n-\nGrand Forks, North Dakota, Estados Unidos, 58201\n- Altru Health Systems\n-\n-\nOhio\n-\nToledo, Ohio, Estados Unidos, 43623-3456\n- CCOP - Toledo Community Hospital Oncology Program\n-\n-\nSouth Dakota\n-\nRapid City, South Dakota, Estados Unidos, 57709\n- Rapid City Regional Hospital\n-\nSioux Falls, South Dakota, Estados Unidos, 57105-1080\n- CCOP - Sioux Community Cancer Consortium\n-\n-\nCriterios de participaci\u00f3n\nCriterio de elegibilidad\nEdades elegibles para estudiar\nAcepta Voluntarios Saludables\nG\u00e9neros elegibles para el estudio\nDescripci\u00f3n\nCARACTER\u00cdSTICAS DE LA ENFERMEDAD: Carcinoma de c\u00e9lulas de transici\u00f3n de vejiga resecado histol\u00f3gicamente confirmado en estadios 0 y I (Ta, T1 o Tis) Sin enfermedad avanzada o invasi\u00f3n muscular Sin antecedentes de carcinoma de c\u00e9lulas de transici\u00f3n de pr\u00f3stata\nCARACTER\u00cdSTICAS DEL PACIENTE: Edad: A partir de los 18 a\u00f1os Estado funcional: No especificado Esperanza de vida: M\u00e1s de 3 a\u00f1os Hematopoy\u00e9ticas: WBC al menos 3500/mm3 Recuento de plaquetas al menos 100 000/mm3 Hemoglobina al menos 10 g/dL Hep\u00e1tica: Bilirrubina no mayor a 1,5 veces l\u00edmite superior de lo normal (LSN) Fosfatasa alcalina no superior a 3 veces el ULN SGOT no superior a 3 veces el ULN Renal: Creatinina no superior a 1,5 veces el ULN Otro: No embarazadas ni lactantes Las pacientes f\u00e9rtiles deben usar m\u00e9todos anticonceptivos efectivos Al menos 5 a\u00f1os desde la neoplasia maligna previa excepto carcinoma de c\u00e9lulas escamosas o de c\u00e9lulas basales no metast\u00e1sico de la piel Sin antecedentes de interacciones medicamentosas que podr\u00edan afectar la terapia Sin inmunodeficiencia\nTERAPIA CONCURRENTE PREVIA: Terapia biol\u00f3gica: Se requiere BCG intravesical previa (si patolog\u00eda T1 o Tis y citolog\u00eda PAB negativa) Quimioterapia: No especificado Terapia endocrina: No especificado Radioterapia: Sin radioterapia previa en la pelvis Cirug\u00eda: No especificado Otro: Terapia intravesical dentro de los 30 d\u00edas permitido Al menos 30 d\u00edas desde m\u00e1s de 2 multivitam\u00ednicos al d\u00eda\nPlan de estudios\n\u00bfC\u00f3mo est\u00e1 dise\u00f1ado el estudio?\nDetalles de dise\u00f1o\n- Prop\u00f3sito principal: PREVENCI\u00d3N\n- Asignaci\u00f3n: ALEATORIZADO\n- Modelo Intervencionista: PARALELO\n- Enmascaramiento: DOBLE\nArmas e Intervenciones\n|\n|\nGrupo de participantes/brazo\n|\n|\nIntervenci\u00f3n / Tratamiento\n|\n|\nEXPERIMENTAL: Multivitamina\nLos pacientes reciben multivitaminas por v\u00eda oral una vez al d\u00eda durante 3 a\u00f1os. Los pacientes son seguidos cada 3 meses durante 2 a\u00f1os, luego cada 6 meses durante 1 a\u00f1o y luego anualmente a partir de entonces.\n|\n|\nPLACEBO_COMPARADOR: Placebo\nLos pacientes reciben placebo por v\u00eda oral una vez al d\u00eda durante 3 a\u00f1os. Los pacientes son seguidos cada 3 meses durante 2 a\u00f1os, luego cada 6 meses durante 1 a\u00f1o y luego anualmente a partir de entonces.\n\u00bfQu\u00e9 mide el estudio?\nMedidas de resultado primarias\n|\n|\nMedida de resultado\n|\n|\nPeriodo de tiempo\n|\n|\nPrevenci\u00f3n de la recurrencia del c\u00e1ncer de vejiga en etapa temprana\nPeriodo de tiempo: Hasta 5 a\u00f1os\n|\n|\nHasta 5 a\u00f1os\nColaboradores e Investigadores\nPatrocinador\nColaboradores\nInvestigadores\n- Silla de estudio: Michael L. Blute, MD, Mayo Clinic\nFechas de registro del estudio\nFechas importantes del estudio\nInicio del estudio\nFinalizaci\u00f3n primaria (ACTUAL)\nFinalizaci\u00f3n del estudio (ACTUAL)\nFechas de registro del estudio\nEnviado por primera vez\nPrimero enviado que cumpli\u00f3 con los criterios de control de calidad\nPublicado por primera vez (ESTIMAR)\nActualizaciones de registros de estudio\n\u00daltima actualizaci\u00f3n publicada (ESTIMAR)\n\u00daltima actualizaci\u00f3n enviada que cumpli\u00f3 con los criterios de control de calidad\n\u00daltima verificaci\u00f3n\nM\u00e1s informaci\u00f3n\nT\u00e9rminos relacionados con este estudio\nPalabras clave\nT\u00e9rminos MeSH relevantes adicionales\nOtros n\u00fameros de identificaci\u00f3n del estudio\n- NCCTG-979252\n- CDR0000066702 (REGISTRO: PDQ (Physician Data Query))\n- NCI-P98-0138\nEsta informaci\u00f3n se obtuvo directamente del sitio web\n[clinicaltrials.gov](https://clinicaltrials.gov) sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comun\u00edquese con [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Tan pronto como se implemente un cambio en [clinicaltrials.gov](https://clinicaltrials.gov), tambi\u00e9n se actualizar\u00e1 autom\u00e1ticamente en nuestro sitio web. .\nEnsayos cl\u00ednicos sobre C\u00e1ncer de vejiga\n-\nNCT06040762A\u00fan no reclutando\n[Una intervenci\u00f3n de ejercicio de prehabilitaci\u00f3n en el hogar para mejorar la funci\u00f3n f\u00edsica en pacientes que reciben quimioterapia antes de la cistectom\u00eda radical, prueba Get Moving](https://ichgcp.net/es/clinical-trials-registry/NCT06040762)C\u00e1ncer de vejiga en estadio IIIA AJCC v8 | Carcinoma de vejiga con invasi\u00f3n muscular | C\u00e1ncer de vejiga en estadio II AJCC v8\n-\nNCT06032910ReclutamientoHernia | C\u00e1ncer de vejiga | Conducto ileal\n-\n-\nNCT06026332A\u00fan no reclutando\n-\nNCT06026189ReclutamientoC\u00e1ncer de vejiga | Carcinoma urotelial | Hematuria | Neoplasia Urotelial\n-\nNCT06022029A\u00fan no reclutando\n[Un estudio de aumento y expansi\u00f3n de dosis de ONM-501 intratumoral solo y en combinaci\u00f3n con cemiplimab en pacientes con linfomas y tumores s\u00f3lidos avanzados. (ON-5001)](https://ichgcp.net/es/clinical-trials-registry/NCT06022029)Linfoma No Hodgkin | Linfoma folicular | Carcinoma in situ | Linfoma de c\u00e9lulas del manto | C\u00e1ncer metast\u00e1sico | C\u00e1ncer de vejiga | C\u00e1ncer de piel | C\u00e1ncer de mama triple negativo | C\u00e1ncer de cuello uterino | Linfoma difuso de c\u00e9lulas B grandes\n-\nNCT06020651Reclutamiento\n[Toxicidad vascular de los inhibidores de puntos de control inmunol\u00f3gico: de la cama a la mesa de trabajo (VICKI)](https://ichgcp.net/es/clinical-trials-registry/NCT06020651)Carcinoma de c\u00e9lulas renales | C\u00e1ncer | C\u00e1ncer de vejiga | MSI-H C\u00e1ncer\n-\nNCT06011954Reclutamiento\n-\nNCT06009510A\u00fan no reclutando\n-\nNCT06009848Reclutamiento\nEnsayos cl\u00ednicos sobre Placebo\n-\nNCT06041269Reclutamiento\n-\nNCT06041984A\u00fan no reclutandoColonoscopia | Glicopirrolato\n-\nNCT06042270A\u00fan no reclutando\n[Respuestas termorreguladoras de los bomberos en incendios activos con suplementaci\u00f3n con beta\u00edna (FFBET)](https://ichgcp.net/es/clinical-trials-registry/NCT06042270)Inflamaci\u00f3n | Cambios de temperatura corporal | Deshidrataci\u00f3n de agua corporal\n-\nNCT06042257A\u00fan no reclutandoHiperactividad en ni\u00f1os con s\u00edndrome de Down | Impulsividad en ni\u00f1os con s\u00edndrome de Down\n-\nNCT06041152A\u00fan no reclutandoDeterioro cognitivo leve amn\u00e9sico\n-\nNCT06040905A\u00fan no reclutando\n[Efecto causal de la nutrici\u00f3n de la coenzima Q10 y la disfunci\u00f3n cognitiva en la tormenta metab\u00f3lica (hiperglucemia y sarcopenia) y el factor neurotr\u00f3fico derivado del cerebro](https://ichgcp.net/es/clinical-trials-registry/NCT06040905)Hiperglucemia | Enfermedad de Alzheimer | Defecto cognitivo leve | Pre-sarcopenia\n-\nNCT06041217A\u00fan no reclutando\n-\nNCT06042153A\u00fan no reclutandoDiabetes tipo 2 | Enfermedad renal en etapa terminal en di\u00e1lisis\n-\nNCT06041165Reclutamiento\n-\nNCT06041789A\u00fan no reclutando", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/es", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/ich-e-group-of-guidelines", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/events", "https://ichgcp.net/es/clinical-trials-registry/publications", "https://ichgcp.net/es/clinical-trials-registry/researchers", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/clinical-trials-registry/NCT00003623", "https://telegram.me/share/url?url=https://ichgcp.net/es/clinical-trials-registry/NCT00003623&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/es/clinical-trials-registry/NCT00003623", "https://ichgcp.net/es", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Alliance%20for%20Clinical%20Trials%20in%20Oncology", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Bladder%20Cancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=multivitamin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=multivitamin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Placebo", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Alliance%20for%20Clinical%20Trials%20in%20Oncology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%20Cancer%20Institute%20%28NCI%29", "https://ichgcp.net/es/clinical-trials-registry/research/list?term=recurrent%20bladder%20cancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Urologic%20Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Urogenital%20Neoplasms", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Urologic%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Urinary%20Bladder%20Diseases", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Urinary%20Bladder%20Neoplasms", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/es/clinical-trials-registry/NCT06040762", "https://ichgcp.net/es/clinical-trials-registry/NCT06032910", "https://ichgcp.net/es/clinical-trials-registry/NCT06034015", "https://ichgcp.net/es/clinical-trials-registry/NCT06026332", "https://ichgcp.net/es/clinical-trials-registry/NCT06026189", "https://ichgcp.net/es/clinical-trials-registry/NCT06022029", "https://ichgcp.net/es/clinical-trials-registry/NCT06020651", "https://ichgcp.net/es/clinical-trials-registry/NCT06011954", "https://ichgcp.net/es/clinical-trials-registry/NCT06009510", "https://ichgcp.net/es/clinical-trials-registry/NCT06009848", "https://ichgcp.net/es/clinical-trials-registry/NCT06041269", "https://ichgcp.net/es/clinical-trials-registry/NCT06041984", "https://ichgcp.net/es/clinical-trials-registry/NCT06042270", "https://ichgcp.net/es/clinical-trials-registry/NCT06042257", "https://ichgcp.net/es/clinical-trials-registry/NCT06041152", "https://ichgcp.net/es/clinical-trials-registry/NCT06040905", "https://ichgcp.net/es/clinical-trials-registry/NCT06041217", "https://ichgcp.net/es/clinical-trials-registry/NCT06042153", "https://ichgcp.net/es/clinical-trials-registry/NCT06041165", "https://ichgcp.net/es/clinical-trials-registry/NCT06041789", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Jos%25C3%25A9phine%2BSOLTANI%252C%2BCardiology%2Bdepartment%252C%2BVersailles%2BHospital", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidade%2Bde%2BLisboa%252C%2BPortugal", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Center%2Bfor%2BIndustrial%2BTechnological%2BDevelopment%2Bof%2BSpain", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Medtronic%2BSurgical%2BTechnologies", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=SeeCure%2BLLC", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Kaneka%2BAmericas%2BHolding%2BInc.", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Universidad%2Bdel%2BZulia", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=European%2BSociety%2Bof%2BHuman%2BReproduction%2Band%2BEmbryology", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Pediatric%2BOrthopaedic%2BSociety%2Bof%2BNorth%2BAmerica", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/es/clinical-trials-registry/research/list?spons=Orphanetics%2BPharma%2BEntwicklungs%2BGmbH", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Esophageal%2BResection%2BCandidates", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Colon%2BMalignant%2BTumor", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ultrasound%2BEvaluation", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Post-traumatic%2BAnosmia", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Stage%2BI%2BGallbladder%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Cushing%2527s%2BSyndrome%2BI", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Postneoadjuvant%2BTherapy%2BStage%2BI%2BGastric%2BCancer%2BAJCC%2Bv8", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Ankle%2BArthroplasty", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Carcinoma%252C%2BAdrenal%2BCortical", "https://ichgcp.net/es/clinical-trials-registry/research/list?cond=Malignant%2BNeoplasm%2Bof%2BRespiratory%2Band%2BIntrathoracic%2BOrgan%2BCarcinoma", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Pilocarpine%2B1.25%2525%2BEye%2Bdrop", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Valacyclovir%2Barrow", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Transplant%2B2%2BMelphalan", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Oral%2BGlucose%2BGel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=20mg%2BAzilsartan%2BTablets", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Injectafer", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Brimonidine%2Btartrate%2Bophthalmic%2Bsolution%2B0.025%2525%2B%2528n%2B%253D%2B56%2529", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Alpelisib%2B150%2BMG%2BOral%2BTablet%2B%255BPiqray%255D", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=MK-8521%2B100%25CE%25BCg", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Teicoplanin%2BSandoz%2B200%2Bmg%2Bpowder%2Band%2Bsolvent%2Bfor%2Bsolution%2Bfor%2Binjection%2Bor%2Binfusion%2Bor%2Boral%2Bsolution.", "https://ichgcp.net/es/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/cro-list/country/burundi", "https://ichgcp.net/es/cro-list/country/czech_republic", "https://ichgcp.net/es/cro-list/country/ethiopia", "https://ichgcp.net/es/cro-list/country/germany", "https://ichgcp.net/es/cro-list/country/ireland", "https://ichgcp.net/es/cro-list/country/lithuania", "https://ichgcp.net/es/cro-list/country/myanmar", "https://ichgcp.net/es/cro-list/country/paraguay", "https://ichgcp.net/es/cro-list/country/sweden", "https://ichgcp.net/es/cro-list/country/taiwan", "https://ichgcp.net/es/cro-list/country/tunisia", "https://ichgcp.net/es/cro-list/country/united_arab_emirates", "https://ichgcp.net/es/cro-list/country/zimbabwe", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/cro-list/country/mongolia/company/sgs", "https://ichgcp.net/es/cro-list/country/mongolia", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/es/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/es", "https://ichgcp.net/es/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/es/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/es/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/es/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/es/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/es/cro-list", "https://ichgcp.net/es/pharma-list", "https://ichgcp.net/es/labs", "https://ichgcp.net/es/service-companies", "https://ichgcp.net/es/cra-jobs", "https://ichgcp.net/es/clinical-trials-registry", "https://ichgcp.net/es/eu-clinical-trials-registry", "https://ichgcp.net/es/publications", "https://ichgcp.net/es/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/es/sitemap", "https://ichgcp.net/es/contact-us", "https://ichgcp.net/es/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT00003623", "https://ichgcp.net/de/clinical-trials-registry/NCT00003623", "https://ichgcp.net/clinical-trials-registry/NCT00003623", "https://ichgcp.net/es/clinical-trials-registry/NCT00003623", "https://ichgcp.net/fr/clinical-trials-registry/NCT00003623", "https://ichgcp.net/it/clinical-trials-registry/NCT00003623", "https://ichgcp.net/hu/clinical-trials-registry/NCT00003623", "https://ichgcp.net/nl/clinical-trials-registry/NCT00003623", "https://ichgcp.net/no/clinical-trials-registry/NCT00003623", "https://ichgcp.net/pl/clinical-trials-registry/NCT00003623", "https://ichgcp.net/pt/clinical-trials-registry/NCT00003623", "https://ichgcp.net/fi/clinical-trials-registry/NCT00003623", "https://ichgcp.net/sv/clinical-trials-registry/NCT00003623", "https://ichgcp.net/cs/clinical-trials-registry/NCT00003623", "https://ichgcp.net/ru/clinical-trials-registry/NCT00003623", "https://ichgcp.net/ja/clinical-trials-registry/NCT00003623", "https://ichgcp.net/zh/clinical-trials-registry/NCT00003623", "https://ichgcp.net/ko/clinical-trials-registry/NCT00003623", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}